Hints and tips:
...A spokesperson for Merck Sharp & Dohme – the name under which the US group operates in Europe – said it is cooperating fully with the CMA’s investigation, and said: MSD is confident that the proceedings...
...Mergers led the US company to become known as Merck Sharp & Dohme, which prompted a 1950s agreement for it to keep exclusive rights to the Merck name in North America while calling itself MSD everywhere...
...Mergers led the US company to become known as Merck Sharp & Dohme, and this spurred a 1950s agreement for it to keep exclusive rights to the family name in North America while calling itself MSD everywhere...
...Merck’s outperformance stands in sharp contrast to rival Pfizer, which cut its full-year guidance after it warned that a strengthening dollar was hurting its performance....
...Earnings Caterpillar Q4 $1.70 ($2.32) Monsanto Q4 $2.58 ($2.28) Ryanair Holdings Q3 €0.00 (€0.01) ●Attention will focus on how far a sharp fall-off in European sales has hurt Ford Motor when the US’...
...These sharp losses weighed on the S&P healthcare index, which fell0.5 per cent to 371.88....
...Rival Merck was also higher, rising 1.5 per cent to $35.81 as it reported first- quarter earnings that also beat estimates....
...A rally among financial stocks helped Wall Street to shrug off a sharp drop in the oil price and push higher on Wednesday....
...Analysis of the bidders’ operational performance one year before a deal and three years after the combined group was created showed a sharp deterioration....
...Bristol-Myers Squibb gave up 2.9 per cent to $22.12, while Merck lost 1.7 per cent to $32.32....
...He also sees a sharp rise in trials taking place in developing countries such as China, where costs are lower and it is quicker to find patients....
...Withdrawing the rights outside the US and Asia from Schering-Plough of Remicade would mark a sharp blow to Merck’s acquisition by reducing annual sales by more than $2bn and sacrificing sales forecast after...
...Sanofi-Aventis rose 3.4 per cent to €46.42 and Merck gained 2.6 per cent to €68.60....
...Macy’s and JC Penney– both of which disclosed sharp drops in like-for-like sales – advanced 6 per cent to $7.83 and 7.5 per cent to $19.88, respectively....
...Fuelled by safety concerns since the withdrawal in 2004 of Vioxx, Merck’s painkiller, and scares last year around Avandia, GlaxoSmithKline’s diabetes treatment, companies accuse the US Food & Drug Administration...
...Radical government measures to help mortgage companies Fannie Mae and Freddie Mac and a sharp drop in oil prices also helped....
...US stocks recovered from sharp early losses on Friday and edged into record territory as solid earnings updates helped investors shrug off concerns about the Chinese economy....
...Healthcare stocks Merck , down 1.3 per cent at $52.71, and Pfizer , off 0.5 per cent at $27.41, both weighed on the blue-chip benchmark....
...Merck ’s stock advanced after the drugmaker raised its earnings forecast for the year. Its shares were 2.3 per cent higher at $44.15....
...Merck said fourth quarter profits fell 58 per cent and the results just missed forecasts. Its stock fell 1.3 per cent to $44.91....
...drugs with Merck....
...Major pharmaceutical groups have also surged, with Merck rising 18 per cent, Pfizer 15 per cent and Forest Labs 34 per cent....
...The gains would have been more impressive but for sharp afternoon selling of pharmaceutical group Merck , which lost 5.7 per cent to $38.83 after a state judge allowed a retrial for a man who blamed his...
...Shares in HCA, which reported a sharp fall in second-quarter earnings, gained 3.4 per cent to $49.48. Other stocks in the healthcare sector were also higher....
...Merck weighed on the blue-chip index....
International Edition